| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell Biology |
Departments of Adult Oncology [G. M., T. K., P. C. M., J. L., G. I. S., B. E. J., R. S.] and Immunobiology [E. T.], Dana-Farber Cancer Institute, and Department of Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Massachusetts 02115; Biosource International, Hopkinton, Massachusetts 01748 [E. S.]; and Department of Biotechnology, Indian Institute of Technology, Kharagpur, West Bengal 721302, India [S. K. G.]
The c-Met receptor tyrosine kinase and its ligand HGF (hepatocyte growth factor) have been shown to be involved in angiogenesis, cellular motility, growth, invasion, and differentiation. The role of c-Met/HGF axis in small cell lung cancer (SCLC) has not been reported previously. We have determined the expression of p170c-Met precursor and p140c-Met ß-chain in seven SCLC cell lines by immunoblotting. We used the SCLC cell line H69, which expressed an abundant amount of c-Met to study the function and downstream effects of c-Met activation. Stimulation of H69 cells with HGF (40 ng/ml, 6-h stimulation) significantly altered cell motility of the SCLC cells with increased formation of filopodia and membrane ruffling, characterized as membrane blebbing, as well as increased migration of the cellular clusters were seen. We have further studied the signal transduction pathways of HGF/c-Met in the H69 cell line. The stimulation of H69 with HGF (40 ng/ml, >24 h, maximal at 1 h) increased the amount of reactive oxygen species formed by 34%. HGF stimulation (40 ng/ml, 7.5-min stimulation) of H69 cells showed increased tyrosine phosphorylated bands identified at Mr 68,000, 120,000–140,000, and 200,000. Some of these tyrosine-phosphorylated bands were identified as the focal adhesion proteins paxillin, FAK, PYK2, and the c-Met receptor itself. Phospho-specific antibodies show that tyrosines at amino acid (a.a.) 31 of paxillin, and autophosphorylation sites at a.a. 397 of p125FAK, and a.a. 402 of PYK2 are phosphorylated in response to HGF/c-Met signaling. We also demonstrate that the Hsp90 inhibitor geldanamycin, which also affects c-Met, reduced the growth and viability of four of four SCLC cell lines by 25% to 85%, over a 72-h time period. Geldanamycin caused apoptosis of SCLC cells, as well as led to increased levels of Hsp70 but not Hsp90. These results demonstrate that c-Met/HGF pathway is functional in SCLC, and it would be useful to target this pathway toward novel therapy.
This article has been cited by other articles:
|
|
 |
|
  P. A. Zucali, M. G. Ruiz, E. Giovannetti, A. Destro, M. Varella-Garcia, K. Floor, G. L. Ceresoli, J. A. Rodriguez, I. Garassino, P. Comoglio, et al. Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors Ann. Onc., September 1, 2008; 19(9): 1605 - 1612. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Tiran, A. Oren, C. Hermesh, G. Rotman, Z. Levine, H. Amitai, T. Handelsman, M. Beiman, A. Chen, D. Landesman-Milo, et al. A Novel Recombinant Soluble Splice Variant of Met Is a Potent Antagonist of the Hepatocyte Growth Factor/Scatter Factor-Met Pathway Clin. Cancer Res., July 15, 2008; 14(14): 4612 - 4621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Engelman and P. A. Janne Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Clin. Cancer Res., May 15, 2008; 14(10): 2895 - 2899. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Peruzzi and D. P Bottaro Targeting the c-Met Signaling Pathway in Cancer Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 61 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Jagadeeswaran, H. Surawska, S. Krishnaswamy, V. Janamanchi, A. C. Mackinnon, T. Y. Seiwert, S. Loganathan, R. Kanteti, T. Reichman, V. Nallasura, et al. Paxillin Is a Target for Somatic Mutations in Lung Cancer: Implications for Cell Growth and Invasion Cancer Res., January 1, 2008; 68(1): 132 - 142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Salgia c-Met Receptor Tyrosine Kinase as a Therapeutic Target in Cancer ASCO Educational Book, January 1, 2008; 2008(1): 113 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Puri, S. Ahmed, V. Janamanchi, M. Tretiakova, O. Zumba, T. Krausz, R. Jagadeeswaran, and R. Salgia c-Met Is a Potentially New Therapeutic Target for Treatment of Human Melanoma Clin. Cancer Res., April 1, 2007; 13(7): 2246 - 2253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. M. Linehan, P. A. Pinto, R. Srinivasan, M. Merino, P. Choyke, L. Choyke, J. Coleman, J. Toro, G. Glenn, C. Vocke, et al. Identification of the Genes for Kidney Cancer: Opportunity for Disease-Specific Targeted Therapeutics Clin. Cancer Res., January 15, 2007; 13(2): 671s - 679s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hiscox, N. J Jordan, W. Jiang, M. Harper, R. McClelland, C. Smith, and R. I Nicholson Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions Endocr. Relat. Cancer, December 1, 2006; 13(4): 1085 - 1099. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Cassinelli, C. Lanzi, G. Petrangolini, M. Tortoreto, G. Pratesi, G. Cuccuru, D. Laccabue, R. Supino, S. Belluco, E. Favini, et al. Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1. Mol. Cancer Ther., September 1, 2006; 5(9): 2388 - 2397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Germano, D. Barberis, M. M. Santoro, L. Penengo, A. Citri, Y. Yarden, and G. Gaudino Geldanamycins Trigger a Novel Ron Degradative Pathway, Hampering Oncogenic Signaling J. Biol. Chem., August 4, 2006; 281(31): 21710 - 21719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. P. Stabile, J. S. Lyker, S. R. Land, S. Dacic, B. A. Zamboni, and J. M. Siegfried Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer Carcinogenesis, August 1, 2006; 27(8): 1547 - 1555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. W. Bauer, R. J. Somcio, F. Fan, W. Liu, M. Johnson, D. P. Lesslie, D. B. Evans, G. E. Gallick, and L. M. Ellis Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells. Mol. Cancer Ther., July 1, 2006; 5(7): 1676 - 1682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Peruzzi and D. P. Bottaro Targeting the c-Met Signaling Pathway in Cancer. Clin. Cancer Res., June 15, 2006; 12(12): 3657 - 3660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Jagadeeswaran, P. C. Ma, T. Y. Seiwert, S. Jagadeeswaran, O. Zumba, V. Nallasura, S. Ahmed, R. Filiberti, M. Paganuzzi, R. Puntoni, et al. Functional Analysis of c-Met/Hepatocyte Growth Factor Pathway in Malignant Pleural Mesothelioma Cancer Res., January 1, 2006; 66(1): 352 - 361. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Rossi, A. Cavazza, A. Marchioni, L. Longo, M. Migaldi, G. Sartori, N. Bigiani, L. Schirosi, C. Casali, U. Morandi, et al. Role of Chemotherapy and the Receptor Tyrosine Kinases KIT, PDGFR{alpha}, PDGFR{beta}, and Met in Large-Cell Neuroendocrine Carcinoma of the Lung J. Clin. Oncol., December 1, 2005; 23(34): 8774 - 8785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Mukohara, G. Civiello, I. J. Davis, M. L. Taffaro, J. Christensen, D. E. Fisher, B. E. Johnson, and P. A. Janne Inhibition of the Met Receptor in Mesothelioma Clin. Cancer Res., November 15, 2005; 11(22): 8122 - 8130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-L. Cheng, M.-Y. Chang, S.-Y. Huang, C.-C. Sheu, E.-L. Kao, Y.-J. Cheng, and I.-W. Chong Overexpression of Circulating c-Met Messenger RNA Is Significantly Correlated With Nodal Stage and Early Recurrence in Non-Small Cell Lung Cancer Chest, September 1, 2005; 128(3): 1453 - 1460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Jia, L. Barbier, H. Stuart, M. Amraei, S. Pelech, J. W. Dennis, P. Metalnikov, P. O'Donnell, and I. R. Nabi Tumor Cell Pseudopodial Protrusions: LOCALIZED SIGNALING DOMAINS COORDINATING CYTOSKELETON REMODELING, CELL ADHESION, GLYCOLYSIS, RNA TRANSLOCATION, AND PROTEIN TRANSLATION J. Biol. Chem., August 26, 2005; 280(34): 30564 - 30573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. Ma, R. Jagadeeswaran, S. Jagadeesh, M. S. Tretiakova, V. Nallasura, E. A. Fox, M. Hansen, E. Schaefer, K. Naoki, A. Lader, et al. Functional Expression and Mutations of c-Met and Its Therapeutic Inhibition with SU11274 and Small Interfering RNA in Non-Small Cell Lung Cancer Cancer Res., February 15, 2005; 65(4): 1479 - 1488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Hopkins, M. Bruewer, G. T. Brown, A. A. Pineda, J. J. Ha, L. M. Winfree, S. V. Walsh, B. A. Babbin, and A. Nusrat Epithelial cell spreading induced by hepatocyte growth factor influences paxillin protein synthesis and posttranslational modification Am J Physiol Gastrointest Liver Physiol, October 1, 2004; 287(4): G886 - G898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Schag, S. M. Schmidt, M. R. Muller, T. Weinschenk, S. Appel, M. M. Weck, F. Grunebach, S. Stevanovic, H.-G. Rammensee, and P. Brossart Identification of C-Met Oncogene as a Broadly Expressed Tumor-Associated Antigen Recognized by Cytotoxic T-Lymphocytes Clin. Cancer Res., June 1, 2004; 10(11): 3658 - 3666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Shinomiya and G. F. Vande Woude Suppression of Met Expression: A Possible Cancer Treatment: Commentary re: S. J. Kim et al., Reduced c-Met Expression by an Adenovirus Expressing a c-Met Ribozyme Inhibits Tumorigenic Growth and Lymph Node Metastases of PC3-LN4 Prostate Tumor Cells in an Orthotopic Nude Mouse Model. Clin. Cancer Res., 14: 5161-5170, 2003. Clin. Cancer Res., November 1, 2003; 9(14): 5085 - 5090. [Full Text] [PDF]
|
|
|
|
|
|
P. C. Ma, T. Kijima, G. Maulik, E. A. Fox, M. Sattler, J. D. Griffin, B. E. Johnson, and R. Salgia c-MET Mutational Analysis in Small Cell Lung Cancer: Novel Juxtamembrane Domain Mutations Regulating Cytoskeletal Functions Cancer Res., October 1, 2003; 63(19): 6272 - 6281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sattler, Y. B. Pride, P. Ma, J. L. Gramlich, S. C. Chu, L. A. Quinnan, S. Shirazian, C. Liang, K. Podar, J. G. Christensen, et al. A Novel Small Molecule Met Inhibitor Induces Apoptosis in Cells Transformed by the Oncogenic TPR-MET Tyrosine Kinase Cancer Res., September 1, 2003; 63(17): 5462 - 5469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Pace, L. J. Garcia-Marin, J. A. Tapia, M. J. Bragado, and R. T. Jensen Phosphospecific Site Tyrosine Phosphorylation of p125FAK and Proline-rich Kinase 2 Is Differentially Regulated by Cholecystokinin Receptor Type A Activation in Pancreatic Acini J. Biol. Chem., May 23, 2003; 278(21): 19008 - 19016. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kijima, G. Maulik, P. C. Ma, E. V. Tibaldi, R. E. Turner, B. Rollins, M. Sattler, B. E. Johnson, and R. Salgia Regulation of Cellular Proliferation, Cytoskeletal Function, and Signal Transduction through CXCR4 and c-Kit in Small Cell Lung Cancer Cells Cancer Res., November 1, 2002; 62(21): 6304 - 6311. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
